Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

245 results about "Nsclc cell" patented technology

Application of PDLIM4 gene in preparation of medicine for inhibiting proliferation of non-small cell lung cancer

The invention provides application of a PDLIM4 gene in preparation of a medicine for inhibiting non-small cell lung cancer proliferation, belongs to the technical field of cancer suppressor gene research, and finds that the PDLIM4 gene is highly expressed in non-small cell lung cancer tumors, and the prognosis of a patient with the highly expressed PDLIM4 gene is good; the proliferation of the non-small cell lung cancer cells overexpressed with the PDLIM4 gene is inhibited, and the proliferation of the non-small cell lung cancer cells knocked down with the PDLIM4 gene is accelerated, so that the reagent capable of realizing the overexpression of the PDLIM4 gene is confirmed to be of great significance for inhibiting the proliferation of the non-small cell lung cancer cells. The overexpression of the PDLIM4 gene in the non-small cell lung cancer cells can enhance the chemotherapy effect of the chemotherapy drug adriamycin, and can be used as a chemotherapy sensitizer. The BRD4 is an upstream regulatory factor for increasing the expression of the PDLIM4 gene in the non-small cell lung cancer, and can be used for promoting the expression of the PDLIM4 gene.
Owner:AFFILIATED HOSPITAL OF GUANGDONG MEDICAL UNIV

Molecular imaging probe for diagnosing lung cancer and preparation method thereof

ActiveCN119144608ARealize non-invasive visual detectionImprove stabilitySugar derivativesX-ray constrast preparationsAptamerCancer cell
The invention belongs to the field of molecular imaging probes for cancer diagnosis, and discloses a targeted nucleic acid aptamer aiming at tumor-associated calcium channel sensing protein 2, a molecular imaging probe for diagnosing lung cancer and a preparation method of the molecular imaging probe. The nucleic acid aptamer contains 46 nucleotides, can specifically target the surface Trop-2 of a lung cancer tumor cell, has a specific targeting recognition effect with Trop-2 overexpressed lung cancer cells such as non-small cell lung cancer cells H1650 and small cell lung cancer cells SBC-2, and can be used for molecular imaging of Trop-2 positive lung cancer patients. The molecular imaging probe can be used for noninvasive visual molecular imaging of lung cancer, and has the advantages of high specificity, high sensitivity, good imaging effect and the like. The preparation method of the molecular imaging probe is simple in reaction condition, low in cost and easy for clinical transformation.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Application of pitavastatin in preparation of medicine for reversing multidrug resistance of tumor

The invention discloses an application of pitavastatin in preparation of a medicine for reversing multidrug resistance of tumors. The invention discovers that pitavastatin can significantly enhance the sensitivity of oxaliplatin-resistant human colorectal cancer cells to a plurality of tumor chemotherapeutic drugs (including oxaliplatin, irinotecan and regorafenib), and reverse the multidrug resistance of oxaliplatin-resistant human colorectal cancer. The invention also finds that pitavastatin can obviously enhance the sensitivity of the cis-platinum drug-resistant human non-small cell lung cancer cells to various tumor chemotherapeutic drugs (including cis-platinum, oxaliplatin and paclitaxel) and reverse the multidrug resistance of the cis-platinum drug-resistant human non-small cell lung cancer. Therefore, pitavastatin has an application prospect of being developed into drugs for reversing multidrug resistance of tumors.
Owner:CHINA PHARM UNIV

Application of AMPK inhibitor and ferroptosis inducer combined drug in tumor treatment

The invention relates to an application of an AMPK inhibitor and ferroptosis inducer combined drug in tumor treatment, in particular to an application of a ferroptosis inducer (RSL3) combined AMPK inhibitor (Compound C) in preparation of a drug for tumor treatment, and belongs to the technical field of biological medicine. In-vivo and in-vitro experiments prove that the combination of a ferroptosis inducer (RSL3) and an AMPK inhibitor (Compound C) drug can significantly inhibit the proliferation of non-small cell lung cancer cells with high expression of MORC2. The drug combination exerts significant synergistic interaction, and has more effective tumor treatment effect than a single drug. Therefore, the combination of the ferroptosis inducer and the cell metabolism inhibitor serves as a new potential clinical treatment strategy, and a new thought is provided for tumor treatment of high-expression MORC2.
Owner:CHIMEDICAL UNIVERSITY

Alkaloid compound as well as preparation method and anti-tumor application thereof

The invention provides an alkaloid compound as well as a preparation method and an application thereof in tumor resistance. The alkaloid compound provided by the invention shows a remarkable cytotoxic effect on human non-small cell lung cancer cells A549, mouse lung adenocarcinoma cells Lewis, human triple negative breast cancer cells MDA-MB-231 and mouse breast cancer cells 4T1, and can be used for preparing medicines for treating breast cancer, lung cancer and the like.
Owner:CHINESE MEDICINE GUANGDONG LABORATORY +1

EGFR (Epidermal Growth Factor Receptor) mutation-targeted dimethyl phosphine oxide substituted aniline pyrimidine derivative, preparation method and application thereof and medicine prepared from EGFR mutation-targeted dimethyl phosphine oxide substituted aniline pyrimidine derivative

The invention belongs to the technical field of medicines, and relates to a dimethyl phosphine oxide substituted aniline pyrimidine derivative targeting EGFR mutation, a preparation method and application thereof, and a medicine prepared from the dimethyl phosphine oxide substituted aniline pyrimidine derivative. The invention provides a compound as shown in a formula I. The compounds have outstanding inhibitory activity (at a nanomole level) and selectivity on EGFRT790M / C797S / L858R kinase and EGFRL858R / T790M kinase, have an obvious inhibitory effect on a non-small cell lung cancer cell line, particularly have outstanding selectivity on EGFR mutant cells H1975, and have an obvious inhibitory effect. The compound disclosed by the invention has a remarkable tumor inhibition effect in a nude mouse heterophylloma model and is relatively low in in-vivo toxicity. Therefore, the compound provided by the invention can be used as an epidermal growth factor receptor tyrosine kinase inhibitor to be applied to preparation of anti-lung cancer drugs, and has a good application prospect. And the formula I of the # imgabs0 # is shown in the specification.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Coumarin KRAS-G12C inhibitor as well as preparation and application thereof

The invention discloses a coumarin KRAS-G12C inhibitor as well as preparation and application of the coumarin KRAS-G12C inhibitor. The coumarin compound disclosed by the invention has a remarkable inhibition effect on non-small cell lung cancer cells (NCI-H23 and NCI-H358) with high expression of KRAS-G12C and pancreatic cancer cells (MIAPaCa-2), is particularly used for preparing medicines for treating and / or preventing non-small cell lung cancer and pancreatic cancer, and has a good prospect of development and application of antitumor medicines.
Owner:LANZHOU UNIV

TRIM27 protein expression inhibitor and application thereof in preparation of medicine for treating non-small cell lung cancer and regulation and control of stability and / or expression level of TP53 protein

The invention relates to the technical field of biological medicine. The invention provides a TRIM27 protein expression inhibitor and application thereof in preparation of drugs for treating non-small cell lung cancer and regulation and control of TP53 protein stability and / or expression level. Knock-down of TRIM27 can reduce survival, migration, invasion and dryness of NSCLC cells. Meanwhile, the expression of TP53 can be enhanced by knocking down TRIM27, and the protein level of TP53 is improved, so that the proliferation and dryness of non-small cell lung cancer cells are inhibited; and the ubiquitination level of TP53 can be weakened, and the stability of TP53 protein is enhanced. The method is of great significance to more effective identification of biomarkers and drug targets and NSCLC treatment.
Owner:JIAXING NO 1 HOSPITAL

Preparation of 10-trifluoromethoxy camptothecin derivative and application of 10-trifluoromethoxy camptothecin derivative in anti-tumor aspect

The invention relates to preparation of 10-trifluoromethoxy camptothecin compounds and application of the 10-trifluoromethoxy camptothecin compounds in antitumor drugs. The structural formula of the compounds is shown in the specification. In-vitro cytotoxic activity screening results show that the 10-trifluoromethoxy camptothecin compound has broad-spectrum anti-tumor activity, and shows relatively strong inhibitory activity on human liver cancer cells (HepG2), human non-small cell lung cancer cells (A549), human colon cancer cells (SW480), human bile duct cancer cells (QBC939), human breast cancer cells (MCF-7), human pancreatic cancer cells (PANC-1) and human pancreatic cancer cells (BxPC-3). The compound 10-trifluoromethoxy camptothecin I and the compound 7-ethyl-10-trifluoromethoxy camptothecin II have a relatively strong inhibition effect on the detected seven tumor cell lines, and the IC50 (half maximal inhibitory concentration) values of the compound 10-trifluoromethoxy camptothecin I and the compound 7-ethyl-10-trifluoromethoxy camptothecin II are respectively 0.913 to 0.0661 mu M and 4.932 to 0.0578 mu M, which are obviously superior to those of a contrast drug topotecan. Wherein the compound I and the compound II show the strongest inhibitory activity on a BxPC-3 cell line, and the IC50 values of the compound I and the compound II are 0.0661 + / -0.0065 [mu] M and 0.0578 + / -0.0043 [mu] M respectively. Therefore, the 10-trifluoromethoxy camptothecin compound is expected to be developed into a novel antitumor drug. # imgabs0 #
Owner:LANZHOU UNIV

Anticancer composition using flavone derivative

Disclosed is an anticancer composition using a flavone derivative. In the present invention, the flavone derivative exhibits cytotoxicity against: H827, H1299, H522, and A549, which are human non-small cell lung cancer cell lines; MCF-7, which is a human breast cancer cell line; and PANC-1, which is a human pancreatic cancer cell line, in a time-dependent manner and in a treatment concentration-dependent manner, and not only exhibits a synergistic effect when used in combination with other conventional anticancer agents, such as osimertinib, which is an anticancer agent targeting for lung cancer, tamoxifen, which is a hormone agent against breast cancer, and gemcitabine, which is a cytotoxic anticancer agent against pancreatic cancer, but also exhibits the effect of synergistically inhibiting the expression of HIF-1α when used alone or in combination with an existing anticancer agent.
Owner:A CHEMBIO CO LTD

Methods Of Using Alternating Electric Fields And Checkpoint Inhibitors

Disclosed are methods of increasing survival of a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of a checkpoint inhibitor to the subject. Disclosed are methods of treating a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of a checkpoint inhibitor to the subject. In some aspects, the checkpoint inhibitor is Nivolumab, Pembrolizumab, or Atezolizumab. Also disclosed are methods of increasing survival of a subject having non-small cell lung cancer comprising: applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more non-small cell lung cancer cells, and administering a therapeutically effective amount of a checkpoint inhibitor to the subject. Disclosed are methods of treating a subject having non-small cell lung cancer comprising: applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more non-small cell lung cancer cells, and administering a therapeutically effective amount of a checkpoint inhibitor to the subject. In some aspects, the checkpoint inhibitor is ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (trade name Libtayo), and dostarlimab (Jemperli), atezolizumab (Tecentriq), durvalumab (Imfinzi), or avelumab (Bavencio).
Owner:NOVOCURE GMBH

Application of copper death inducer in preparation of medicine for treating osimertinib-resistant non-small cell lung cancer

The invention provides application of a copper death inducer in preparation of a medicine for treating osimertinib-resistant non-small cell lung cancer, and belongs to the technical field of treatment of non-small cell lung cancer. According to the invention, through high-throughput drug screening, the copper death inducer copper diethyl dithiocarbamate (CuET) and osimertinib are combined for use, so that a remarkable synergistic anti-cancer effect is achieved; furthermore, through detection of a wild type and osimertinib drug-resistant cell line model, an osimertinib sensitive and drug-resistant patient-derived organoid and a mouse xenotransplantation model, it is found that the anti-tumor effect of osimertinib can be remarkably enhanced through copper death induction, and osimertinib drug resistance is overcome. According to the technical scheme provided by the invention, osimertinib drug-resistant non-small cell lung cancer cells can be effectively killed, the curative effect of osimertinib in sensitive and drug-resistant models is remarkably enhanced, and an application scene is provided for copper death in tumor treatment.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Sea cucumber flower source targeted EGFR (epidermal growth factor receptor) anti-tumor active peptide as well as screening method and application thereof

The invention belongs to the technical field of biology, and discloses a bioactive peptide which is a micromolecular anti-tumor bioactive peptide derived from sea cucumber, and the amino acid sequence of the bioactive peptide is FNPDTFD. Sephadex G-15 gel chromatography and mass spectrometry technologies are used for separating, purifying and structurally identifying the sea cucumber flower enzymolysis peptide, so that the small molecule peptide with a potential anti-tumor effect is obtained. A cell viability experiment verifies that the small molecule peptide can selectively inhibit the proliferation of EGFR mutant non-small cell lung cancer cells. Besides, molecular docking and protein immunoblotting results show that the peptide can be combined with EGFR mutant protein, and the activation of a downstream Akt / mTOR signal channel is inhibited by targeting the EGFR mutant protein, so that the biological activity of resisting the non-small cell lung cancer is exerted. The bioactive peptide not only has the potential of being developed into a new generation of EGFR targeting antitumor drugs, but also has wide application prospects in the field of functional health food. The preparation process is simple, and is suitable for industrial production and market popularization and application.
Owner:SHANGHAI OCEAN UNIV

SOD2 knockout cell line and application thereof in anti-poxvirus

The invention discloses an SOD2 knockout cell line and application of the SOD2 knockout cell line in anti-poxvirus, and relates to the technical field of antiviral research. According to the invention, sgRNA of targeted superoxide dismutase 2 (SOD2) is designed, the sequence of the sgRNA is shown as SEQ ID NO.1-SEQ ID NO.2, then a stable SOD2 knockout human-derived non-small cell lung cancer A549 cell line is established by combining CRISPR / Cas9 gene editing with a lentiviral vector delivery technology, single-cell cloning is obtained through multiple rounds of puromycin screening, and the SOD2 gene knockout A549 cell strain is successfully constructed. Vaccinia virus Tian Tan strain infection shows that the number of plaques of SOD2 knockout cells is obviously greater than that of the plaques (about 2.3 times) of normal cell infection, and the plaques are relatively large, so that fine SOD2 has the effect of limiting intercellular transmission of poxvirus. The invention lays a foundation for research and preparation of antiviral drugs.
Owner:INST OF ANIMAL HEALTH GUANGDONG ACADEMY OF AGRI SCI

Application of ZDHHC11 gene in preparation of medicine for treating non-small cell lung cancer

The invention discloses an application of a ZDHHC11 gene in preparation of a medicine for treating non-small cell lung cancer, and relates to the technical field of biological medicines, and the research finds that the ZDHHC11 protein level is increased by over-expressing the ZDHHC11 gene in NSCLC cells, the cell viability, migration ability and multiplication ability can be inhibited, and cell apoptosis can be promoted. The activity of NSCLC cells can be increased by knocking out the ZDHHC11 gene, and the result shows that the ZDHHC11 gene plays an important role in controlling the development process of the non-small cell lung cancer, provides a new action target for treating the NSCLC, and has potential application value in preparing the medicine for treating the non-small cell lung cancer.
Owner:ANHUI UNIV

5, 9-di-tert-butyl naphtho-indolizino phenothiazine compound as well as preparation method and application thereof

The invention relates to a 5, 9-di-tert-butyl naphtho-indolizine phenothiazine compound as well as a preparation method and medical application thereof. The compound is efficiently synthesized through Ullmann coupling and palladium-catalyzed intramolecular arylation reaction. In-vitro anti-tumor activity research shows that the compound has remarkable selective inhibitory activity on various human tumor cell lines, and particularly, the inhibitory effect on non-small cell lung cancer A549 cells (IC50 = 0.21 mu M) is improved by two orders of magnitude compared with that of cis-platinum; iC50 (half maximal inhibitory concentration) of other cell lines are as follows: 1.26 mu M of prostate cancer PC-3 cells, 6.78 mu M of liver cancer HepG2 cells, 7.99 mu M of cervical cancer Hela cells and 25.46 mu M of breast cancer MCF-7 cells. Preliminary toxicity experiments prove that the compound has the characteristic of low cytotoxicity. The compound can be used as a novel high-efficiency low-toxicity anti-tumor lead compound, and provides an important structural basis for the development of anti-cancer drugs.
Owner:NANJING FORESTRY UNIV

Application of STAT1 / 3 inhibitor in preparation of medicine for improving cis-platinum drug resistance

The invention provides an application of an STAT1 / 3 inhibitor in preparation of a medicine for improving cis-platinum drug resistance, and an application of nifurazil and cis-platinum as STAT1 / 3 inhibitors in preparation of a combined medicine for treating tumors with cis-platinum drug resistance. The key DNA damage response protein for regulating and controlling the non-small cell lung cancer cell cis-platinum drug resistance is designed and determined, the key small molecule inhibitor nifurazil for enhancing the drug effect of cis-platinum on drug-resistant cells is screened out, the nifurazil is combined with cis-platinum to be used for treating cis-platinum drug-resistant tumors, the synergistic interaction effect is achieved, and the application prospect is wide. A new thought is provided for overcoming the tumor drug resistance.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Actinomycetes-derived polyketone compound as well as preparation method and application thereof

The invention discloses a polyketone compound derived from actinomycetes as well as a preparation method and application thereof, and relates to the technical field of microbial natural product mining and biological medicine, and the key point of the technical scheme is that the invention discloses a novel polyketone compound Strepactone derived from actinomycetes Streptomyces sp. DP0001, and the molecular formula of the novel polyketone compound Strepactone is C25H38O5. The compound is obtained through strain fermentation, ethyl acetate extraction and multi-step chromatographic purification, and the structure is identified through ESI-MS, 1H NMR and 13C NMR. Experiments show that Strepactone has an inhibition effect on staphylococcus aureus and methicillin-resistant staphylococcus aureus and has remarkable inhibition activity on human non-small cell lung cancer A549 cells, the half inhibitory concentration IC50 of the Strepactone is 5.36 mu M, and the Strepactone has no obvious cytotoxic activity on human embryo kidney cells 293T cells at the concentration of 30 mu M. The compound provided by the invention can be used for preparing anti-drug-resistant bacteria drugs and anti-human non-small cell lung cancer drugs, and also provides a structural basis for the development of novel antibacterial and anti-tumor leading drugs.
Owner:GUIZHOU MEDICAL UNIV

Capsaicin compound and preparation method and application thereof

The invention discloses a capsaicin compound and a preparation method and application thereof, the molecular formula of capsaicin Capsivaryine is C16H21NO3, the chemical structure of capsaicin Capsivaryine is as follows, and the capsaicin Capsivaryine compound is a new compound reported for the first time and is prepared by taking mature and dry fruits of capsicum as raw materials through crushing, sieving, silica gel column treatment, D101 macroporous resin treatment and HPLC (High Performance Liquid Chromatography). The compound disclosed by the invention has a certain in-vitro inhibition effect on human breast cancer cells MCF-7, human liver cancer cells HEPG2, human non-small cell lung cancer cells A549 and human ovarian cancer cells SKOV3, and has no toxicity on human normal liver cells L02. The compound is a natural product which is novel in structure and good in activity, has great potential in the anti-tumor aspect, enriches diversity of pepper plants, and provides guidance for research of chemical components of pepper. # imgabs0 #
Owner:SOUTHEAST UNIV

Application of patinopectin-like in preparation of medicine for relieving and / or treating non-small cell lung cancer

The invention relates to the field of biological medicines, and discloses application of patinopectin-like in preparation of a medicine for relieving and / or treating non-small cell lung cancer. Tests find that on the cellular level, the activity of non-small cell lung cancer cells can be reduced, cell migration can be inhibited, and the cell apoptosis process can be activated through treatment with the patinopectin-like; on the protein expression level, apoptosis-related protein can be remarkably activated, non-small cell lung cancer can be effectively treated by adjusting signal channels such as EGFR / PI3K / AKT, the possibility that tumor cells escape in treatment can be reduced, and therefore the clinical treatment efficiency is improved, and the application prospect is extremely good.
Owner:TSINGHUA SHENZHEN INTERNATIONAL GRADUATE SCHOOL

Preparation and application of novel pyrimidine KRAS G12C inhibitor

The invention discloses a novel pyrimidine KRAS-G12C inhibitor as well as a preparation method and application of the novel pyrimidine KRAS-G12C inhibitor. The pyrimidine compound disclosed by the invention has a remarkable inhibition effect on non-small cell lung cancer cells (NCI-H23 and NCI-H358) with high expression of KRAS-G12C, is particularly used as a medicine for treating and / or preventing the non-small cell lung cancer, is simple and efficient in preparation route, and has a good antitumor medicine development and application prospect.
Owner:LANZHOU UNIV

Use of raltitrexed in the manufacture of a medicament for the treatment of a disease caused by an adenovirus infection

ActiveCN120983440BEnhanced inhibitory effectImprove pathological conditionsOrganic active ingredientsAntiviralsRaltitrexedCancer research
The present application provides the use of raltitrexed in the manufacture of a medicament for the treatment of diseases caused by adenovirus infection, including but not limited to respiratory tract infection, gastrointestinal infection and keratitis caused by adenovirus. When raltitrexed was tested for its anti-adenovirus activity at the cellular level, using a viral infection dose of 100 TCID50, the viral infectivity was determined on a human non-small cell lung cancer cell line (A549 cell) model, and the results showed that raltitrexed had a significant inhibitory effect on adenovirus, with an EC 50 = 8.98 nM, a CC 50 > 187.5 nM, and it was found that it had a significant inhibitory effect on the entry of the virus into the cell; and in the hDSG2 mouse model, a significant inhibitory effect of raltitrexed on viral replication was also observed. Therefore, raltitrexed can be used to treat diseases caused by adenovirus infection.
Owner:BEIJING UNIV OF CHEM TECH

Preparation method and application of tetrahydroindazole antitumor compounds

The present application relates to the technical field of medicine (IPC classification A61P31 / 22), and particularly relates to a preparation method and application of a tetrahydroindazole antitumor compound, the preparation method comprising: reacting a compound of formula I with adamantanol to obtain a 4-(4-hydrazone-3,6,6-trimethyl-1-tetrahydroindazole)-2-(4-hydroxycyclohexylamino) benzamide compound, compared with a 4-(4-hydrazone-3,6,6-trimethyl-1-tetrahydroindazole)-2-(4-hydroxycyclohexylamino) benzamide compound in the prior art, the compound has stronger inhibition of tumor cell growth activity, has generally lower IC50 values, and in particular can significantly reduce the clonogenicity of non-small cell lung cancer at a low concentration, and causes apoptosis of non-small cell lung cancer cells, and has great significance for development of a novel antitumor drug.
Owner:SHENZHEN PEOPLES HOSPITAL

A molecular imaging probe for diagnosing lung cancer and its preparation method

The present invention belongs to the field of molecular imaging probes for cancer diagnosis, and discloses a nucleic acid aptamer targeting tumor-related calcium channel sensor protein 2 and a molecular imaging probe for diagnosing lung cancer and a preparation method thereof. The nucleic acid aptamer contains 46 nucleotides, can specifically target Trop‑2 on the surface of lung cancer tumor cells, and has a specific targeting recognition effect on lung cancer cells overexpressing Trop‑2, such as non-small cell lung cancer cells H1650, small cell lung cancer cells SBC‑2, etc., and can be used for molecular imaging of Trop‑2 positive lung cancer patients. Molecular imaging probes can be used for non-invasive visual molecular imaging of lung cancer, and have the advantages of high specificity, high sensitivity, good imaging effect, etc. The preparation method of the molecular imaging probe has simple reaction conditions, low cost, and easy clinical transformation.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Application of 3 'tRF-mtAsnGTT inhibitor in preparation of medicine for treating osimertinib drug-resistant non-small cell lung cancer

The invention belongs to the field of gene engineering, and particularly designs oligonucleotide and application thereof in preparation of a medicine for treating osimertinib drug-resistant non-small cell lung cancer. Research finds that 3 'tRF-mtAsnGTT is highly expressed in osimertinib drug-resistant non-small cell lung cancer cells, and the inventor designs an effective oligonucleotide capable of specifically inhibiting the function of 3' tRF-mtAsnGTT, so that tumor cell proliferation is inhibited, cell apoptosis is promoted, and the drug sensitivity of the cells to osimertinib is remarkably improved. The invention provides a novel targeting strategy and application approach for molecular intervention and combined treatment of osimertinib resistance of non-small cell lung cancer.
Owner:THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIV

Application of LncRNA as non-small cell lung cancer biomarker and therapeutic target

The invention belongs to the technical field of biological medicine, and particularly relates to application of LncRNA as a non-small cell lung cancer biomarker and a treatment target spot, and the nucleotide sequence of the LncRNA is shown as SEQ ID NO. 1. Experimental results show that proliferation, survival and migration of non-small cell lung cancer cells can be prevented by inhibiting expression of the LncRNA, so that the LncRNA can be used as a non-small cell lung cancer biomarker and a therapeutic target.
Owner:ZHEJIANG UNIV

Tumor hypoxia specific response BODIPY fluorescent probe as well as preparation and application thereof

The invention relates to a tumor hypoxia specific response BODIPY fluorescent probe as well as preparation and application thereof. The invention relates to a BODIPY fluorescent probe which is synthesized by utilizing tumor hypoxia to respond to azobenzene groups. The probe has no signal to normal oxygen cells, shows strong near-infrared fluorescence to hypoxia cancer cells, and can be used for visually detecting deep solid tumors. According to the present invention, the tumor specific response BODIPY fluorescent probe is adopted as the research object, the human liver cancer cells (HepG2) and the human non-small cell lung cancer cells (A549) are adopted as the tested cell strains, the fluorescence detection ability research under the normal oxygen and oxygen deficiency conditions is developed, and the foundation is established for the real-time accurate tumor detection. The fluorescent probe has the advantages of lower preparation cost, simpler synthesis method, easily available raw materials, less side reaction, high yield, easiness in purification, easiness in industrial production and the like.
Owner:PUTIAN UNIV

Heterocyclic compound as well as pharmaceutical composition and application thereof

The invention discloses a heterocyclic compound as well as a pharmaceutical composition and application thereof. Specifically, the present invention discloses a heterocyclic compound represented by formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof. The compound provided by the invention has inhibitory activity on proliferation of one or more of stably transfected cells Ba / F3 KRAS G12C, Ba / F3 KRAS G12D, Ba / F3 KRAS G12V, human pancreatic cancer cells Capan-1, human non-small cell lung cancer cells NCI-H358 (KRAS G12C mutation) and human metastatic pancreatic adenocarcinoma cells AsPC-1 (KRAS G12D mutation) containing KRAS mutation, or the compound provided by the invention has relatively weak inhibitory activity on proliferation of wild PC-9 cells of KRAS. # imgabs0 #
Owner:SHANGHAI ALLIST PHARM CO LTD

Metal complex tailed with immunologically active molecules and its preparation method and application

The present invention discloses a metal complex tailed with an immunologically active molecule, as well as its preparation method and application. The metal complex tailed with an immunologically active molecule exhibits significant anticancer activity. On the one hand, the metal complex exerts cytotoxicity against rapidly growing cancer cells through its active ingredient with anti-tumor immune efficacy. On the other hand, it can also induce immunogenic cell death, enabling the host immune system to attack tumor cells and induce a tumor-specific immune response. (The metal complex of the present invention has been shown to effectively induce immunogenic cell death in non-small cell lung cancer cells and successfully activate anti-tumor immunity in mice in vaccine experiments.) Therefore, the metal complex of the present invention has outstanding effects in anti-cancer, anti-inflammatory, inducing immunogenic cell death, and achieving anti-tumor immunity, and has broad application prospects.
Owner:NANJING NORMAL UNIVERSITY

Methods for the detection and treatment of resistant cancers co-expressing ALPP and / or ALPG / alppl2

Provided are methods for treating treatment-resistant non-small-cell lung cancer (NSCLC) in a patient in need thereof comprising administering a chimeric antigen receptor (CAR) cell therapy, antibody drug conjugate (ADC), or bispecific T cell engager (BiTE) targeting ALPP and / or ALPPL2 in the NSCLC cell, and / or a therapy targeting a genetic mutation selected from an EGFR mutation, a KRAS mutation, a RET mutation, an ALK mutation, a HER2 mutation, a MET mutation, a MEK mutation, an AKT mutation, an ERK mutation, a CDK4 / 6 mutation, a BRAF mutation, and an FGFR mutation.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST